CATALOGO DEI PRODOTTI DELLA RICERCA

TORTORA, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.754
EU - Europa 10.658
AS - Asia 5.047
SA - Sud America 42
OC - Oceania 35
Continente sconosciuto - Info sul continente non disponibili 30
AF - Africa 13
Totale 26.579
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.717
GB - Regno Unito 4.388
CN - Cina 3.292
SG - Singapore 1.328
RU - Federazione Russa 979
IE - Irlanda 961
SE - Svezia 925
FR - Francia 899
IT - Italia 822
DE - Germania 723
FI - Finlandia 605
UA - Ucraina 152
VN - Vietnam 141
BE - Belgio 53
KR - Corea 53
NL - Olanda 43
JP - Giappone 39
ID - Indonesia 38
TR - Turchia 31
AU - Australia 29
CA - Canada 28
EU - Europa 27
IN - India 21
IR - Iran 21
CL - Cile 16
CH - Svizzera 15
HK - Hong Kong 14
AT - Austria 13
BR - Brasile 11
PL - Polonia 11
PE - Perù 10
AZ - Azerbaigian 9
LK - Sri Lanka 9
CZ - Repubblica Ceca 8
SA - Arabia Saudita 8
BG - Bulgaria 6
GR - Grecia 6
LV - Lettonia 6
NZ - Nuova Zelanda 6
RO - Romania 6
UZ - Uzbekistan 6
EE - Estonia 5
MY - Malesia 5
PH - Filippine 5
BD - Bangladesh 4
HU - Ungheria 4
IL - Israele 4
MK - Macedonia 4
MX - Messico 4
TG - Togo 4
AE - Emirati Arabi Uniti 3
CR - Costa Rica 3
DK - Danimarca 3
EC - Ecuador 3
ES - Italia 3
KZ - Kazakistan 3
MA - Marocco 3
NO - Norvegia 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AM - Armenia 2
CM - Camerun 2
EG - Egitto 2
IM - Isola di Man 2
KG - Kirghizistan 2
LT - Lituania 2
LU - Lussemburgo 2
TH - Thailandia 2
A1 - Anonimo 1
BO - Bolivia 1
BY - Bielorussia 1
CO - Colombia 1
JM - Giamaica 1
JO - Giordania 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
PA - Panama 1
PK - Pakistan 1
TM - Turkmenistan 1
TN - Tunisia 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 26.579
Salva come PNG Salva come JPEG
Città #
Southend 4.163
Chandler 1.850
Jacksonville 1.435
Woodbridge 1.405
Singapore 1.133
Ann Arbor 1.008
Dublin 960
Houston 592
Beijing 572
Ashburn 539
Lawrence 396
Princeton 396
Wilmington 377
Jinan 318
Nanjing 277
Shenyang 260
Verona 212
Hebei 166
New York 156
Tianjin 156
Changsha 124
Nanchang 101
Helsinki 96
Haikou 93
Zhengzhou 93
Ningbo 87
Sindelfingen 83
Dong Ket 78
Hangzhou 76
Jiaxing 74
Milan 74
Guangzhou 64
Taizhou 59
Redwood City 58
Norwalk 54
Taiyuan 54
Brussels 53
Santa Clara 51
Boardman 47
Seoul 45
Lanzhou 43
Bologna 41
Los Angeles 41
Seattle 39
Fuzhou 38
Lancaster 38
Jakarta 35
Falls Church 34
Dearborn 32
San Francisco 31
Redmond 29
Tokyo 29
Kent 28
Chicago 27
Dongguan 26
Dallas 23
Washington 23
Moscow 20
Düsseldorf 19
Fairfield 18
Augusta 17
Clearwater 17
Toronto 16
Rome 15
Munich 13
San Mateo 12
Amsterdam 11
Sydney 11
London 10
Melbourne 10
Baku 9
Colombo 9
Detroit 9
Groningen 9
San Diego 9
Frankfurt am Main 8
Nürnberg 8
Padova 8
Shanghai 8
Vienna 8
Ardabil 7
Auburn Hills 7
Bari 7
Canberra 7
Lima 7
Prague 7
Renton 7
Riva 7
Stockholm 7
São Paulo 7
Newark 6
Tashkent 6
Athens 5
Fremont 5
Hong Kong 5
Kochi 5
Leawood 5
Markgröningen 5
Paris 5
Qingdao 5
Totale 18.788
Salva come PNG Salva come JPEG
Nome #
An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients 210
Whole-genome landscape of pancreatic neuroendocrine tumours 173
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs 154
Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment 149
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing 143
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 141
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status 141
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma 138
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations 135
Genomic analyses identify molecular subtypes of pancreatic cancer 134
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel 128
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 127
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 126
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 126
Reporting tumor molecular heterogeneity in histopathological diagnosis 125
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 122
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 121
Tumor thrombosis: a peculiar finding associated with pancreatic neuroendocrine neoplasms. A pictorial essay 120
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis 117
Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study 115
Molecular Pathology of Pancreatic Cancer: from bench-to-bedside translation. 113
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 112
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma 112
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. 111
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling 111
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 111
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 111
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 110
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 110
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 109
Role of Combined Ga-68-DOTATOC and F-18-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors Implications for Managing Surgical Decisions 108
HER2/neu Gene Determination in Women Screened for Breast Carcinoma: How Screening Programs Reduce the Skyrocketing Cost of Targeted Therapy 107
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas 107
Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? 107
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma 106
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 106
Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer 106
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 106
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 104
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance 104
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 104
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-α Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel 104
Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'? 104
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients 103
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 103
Tumor seeding after percutaneous US-guided FNA of solid pancreatic neoplasms 102
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 102
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 102
Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage 102
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 101
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 101
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 101
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients 101
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis 101
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 100
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents 99
Profiling mTOR pathway in neuroendocrine tumors. 99
Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies 99
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 99
Evaluation of cell-free DNA as a biomarker for pancreatic malignancies 99
Adenocarcinoma of the paraurethral glands: a case report 98
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. 97
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration 96
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 96
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach 96
ESGAR 2016 Book of Abstracts 96
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 96
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts 94
R1507, the human monoclonal antibody targeting the Insulin-like Growth Factor Receptor (IGF-1R), in combination with cetuximab can reverse acquired resistance to cetuximab in pancreatic and colon cancer models 94
Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment 94
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 93
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases 93
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 93
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 92
Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice 92
Prognostication and response assessment in liver and pancreatic tumors: The new imaging 92
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 92
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer 91
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials 89
Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. 88
Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy 88
Digital Subtraction of Magnetic Resonance Images Improves Detection and Characterization of Pancreatic Neuroendocrine Neoplasms 88
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 88
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo 88
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes 86
Clinical meta-analyses of targeted therapies in adenocarcinoma. 86
The route to personalized medicine in bladder cancer: where do we stand? 86
Angiogenesis: A target for cancer therapy. 85
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 85
Core curriculum oncologia clinica 85
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy 85
Hypermutation In Pancreatic Cancer 85
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 85
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 83
AR-V7 and prostate cancer: The watershed for treatment selection? 83
Pancreatic neuroendocrine neoplasms: MRI features and correlation with their histological grade 83
8-Chloro-cAMP inhibits transforming growth factor alpha transformation of mammary epithelial cells by restoration of the normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon transformation. 83
The development of PARP as a successful target for cancer therapy 83
Combination of a selective cyclooxygenase-2 inhibitor with EGFR tyrosine kinase inhibitor ZD1839 (‘Iressa’) and Protein Kinase A antisense causes a cooperative antitumor and antiangiogenic effect 82
ZD1839 (Iressa): preclinical studies and pharmacology. 82
Totale 10.513
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.466
article - articoli 90.145
book - libri 236
conference - conferenze 6.885
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.200
Totale 198.932
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.712 0 0 0 0 0 260 335 188 154 297 217 261
2020/20212.991 289 598 130 369 472 235 33 152 143 76 306 188
2021/20222.725 202 780 17 208 94 46 41 175 109 61 198 794
2022/20235.491 472 505 554 860 534 1.409 54 323 582 36 118 44
2023/20242.404 103 200 180 202 381 380 51 232 45 125 353 152
2024/20252.777 400 446 238 1.317 252 124 0 0 0 0 0 0
Totale 26.979